FORMOTEROL/BUDESONIDE/GLYCOPYRRONIUM INHALER (Trixeo AerospaceĀ®)
Clinical Indication
Moderate to severe COPD
Comments
Reviewed by the Respiratory Prescribing Group May 2022
Date of classification
June 2022
Do not prescribe
Drugs not recommended for use in LLR because of lack of evidence of clinical effectiveness, cost prioritization or concerns over safety.